In life sciences, "feeling" ready for the future isn’t a strategy—it’s a risk. Are you actually leading the field? Most organizations are busy, but few know if they’re actually keeping pace with their peers.
We’re officially launching The Innovation Readiness Index: a diagnostic designed to stop the guesswork. We benchmark your capabilities across the 5 pillars that matter:
👉 Trust & Outcomes
👉 Governance & Flow
👉 AI Readiness
In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.
In this webinar, we will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:
"We select patients on biology, but we lose them on circumstance."
That single sentence is the reason Luvida’s hosting a dinner.
We obsess over first patient in. But the metric that actually decides whether a trial succeeds is last patient in, and too often we lose people not because the science failed, but because the trial was never designed around the reality of their lives.
Luvida is a London-based company that integrates social determinants of health data to predict and mitigate clinical trial risk.
The Rosalind Franklin Institute (the Franklin) is a technology institute established by the UK Government as a unique centre committed to advancing tools that are needed to transform healthcare in the future. Through a unique integration of disciplines, we will develop disruptive new technologies designed to tackle major challenges in health and life science. This will accelerate the discovery of new treatments for chronic diseases affecting millions of people around the world.
As our sector continues to navigate change, we’re committed to creating accessible learning opportunities that support our community. Explore our latest courses and webinars, designed to help professionals at every career stage grow, connect, and thrive.
________________________________________________
Spotlight: One Nucleus September Training
Last Chance to Register!
Fierce Biotech at London Life Sciences Week is a one-day event convening 200-250 leaders from across
the global biopharma and investment ecosystem. The event centers on scientific innovation, drug development and dealmaking, creating a platform for life science executives, investors and business development leaders to explore cutting-edge science and strategic partnerships.
Aware of just how busy diaries get for everyone and therefore every trip out of the office or lab must count, we have managed to coordinate with Marks & Clerk, Thermo Fisher Scientific and LBIC to deliver three informative events and peer-to-peer networking opportunities in one day. Three events, three topics, three locations - attend one, two or all three!
Start the Day: Choosing the Right Life Science Room to Be In - A London Seminar
Partnership provides US-based sequencing and scalable consumer genomics infrastructure, including an at-home DNA collection, to deliver PrecisionLife’s personalized wellness reports to US consumers
Interactive Networking Panel, live in Hammersmith London, 15 September, 1730-1930 GMT
Divergence Labs is hiring a full-time Principal Scientist focused on Cell Engineering to join our Antibody Discovery team. We are seeking an experienced candidate with a track record of scientific and professional achievement, including but not limited to 5+ years of industry experience in Cell Engineering with an emphasis on assay development. The role is based in our Cambridge, UK research site and will sit within a unique team with expertise across antibody discovery, cellular and molecular biology, and hardware engineering.
About Divergence